Article Text

PDF
Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002)
  1. Stuart R Cairns1,
  2. John H Scholefield2,
  3. Robert J Steele3,
  4. Malcolm G Dunlop4,
  5. Huw J W Thomas5,
  6. Gareth D Evans6,
  7. Jayne A Eaden7,
  8. Matthew D Rutter8,
  9. Wendy P Atkin9,
  10. Brian P Saunders10,
  11. Anneke Lucassen11,12,
  12. Paul Jenkins13,
  13. Peter D Fairclough14,
  14. Christopher R J Woodhouse15,
  15. developed on behalf of The British Society of Gastroenterology, and the Association of Coloproctology for Great Britain and Ireland
  1. 1Brighton and Sussex University Hospitals, Royal Sussex County Hospital, Brighton, UK
  2. 2Department of GI Surgery, University Hospital, Nottingham, UK
  3. 3Department of Surgery, Ninewells Hospital, Dundee, Scotland, UK
  4. 4Academic Coloproctology, University of Edinburgh, Western General Hospital, Edinburgh, UK
  5. 5St Mark's Hospital, Imperial College, Harrow, Middlesex, UK
  6. 6Academic Unit of Medical Genetics and National Genetics Reference Laboratory, St Mary's Hospital, Hathersage Road, Manchester, UK
  7. 7Walsgrave Hospital, Coventry, UK
  8. 8University Hospital of North Tees, Stockton-on-Tees, Cleveland, UK
  9. 9Imperial College London, St Mary's Campus, London, UK
  10. 10Wolfson Unit of Endoscopy, St Mark's Hospital, Harrow, UK
  11. 11University of Southampton, Southampton, UK
  12. 12Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK
  13. 13Department of Endocrinology, St Bartholomew's Hospital, West Smithfield, London, UK
  14. 14Department of Gastroenterology, St Bartholomew's Hospital, West Smithfield, London, UK
  15. 15University College London, The Royal Marsden Hospital, London, UK
  1. Correspondence to Dr Stuart Cairns, Digestive Diseases Centre, Brighton and Sussex University Hospitals, Royal Sussex County Hospital, Eastern Road, Brighton BN2 5BE, UK; Stuart.cairns{at}bsuh.nhs.uk

Abstract

The British Society of Gastroenterology (BSG) and the Association of Coloproctology for Great Britain and Ireland (ACPGBI) commissioned this update of the 2002 guidance. The aim, as before, is to provide guidance on the appropriateness, method and frequency of screening for people at moderate and high risk from colorectal cancer. This guidance provides some new recommendations for those with inflammatory bowel disease and for those at moderate risk resulting from a family history of colorectal cancer. In other areas guidance is relatively unchanged, but the recent literature was reviewed and is included where appropriate.

  • Colorectal cancer
  • inflammatory bowel disease
  • colorectal adenomas
  • colorectal cancer screening
  • family cancer

Statistics from Altmetric.com

Footnotes

  • All authors identified have contributed to the manuscript as indicated. SC and JHS were co-editors.

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.